Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

Financial Performance - Precigen, Inc. reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.06, and an improvement from a loss of $0.09 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of $1.19 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 2.86%, and down from $1.23 million in the same quarter last year [2] - Over the last four quarters, Precigen has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during this period [2] Stock Performance and Outlook - Precigen shares have increased by approximately 49.1% since the beginning of the year, contrasting with a decline of 4.5% in the S&P 500 [3] - The future performance of Precigen's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $0.8 million, and for the current fiscal year, it is -$0.20 on revenues of $21.9 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Precigen belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]